Akero Therapeutics Inc (STU:0K4)

€ 28.54 -0.79 (-2.69%) Market Cap: 2.03 Bil Enterprise Value: 1.38 Bil PE Ratio: 0 PB Ratio: 2.89 GF Score: 34/100

Akero Therapeutics Inc at JPMorgan Healthcare Conference Transcript
Jan 08, 2024
Akero Therapeutics Inc Phase 2b SYMMETRY Data Presentation Transcript
Oct 10, 2023
Akero Therapeutics Inc at Morgan Stanley Global Healthcare Conference Transcript
Sep 12, 2023
Akero Therapeutics Inc Phase 2b SYMMETRY Cohort D Data Presentation Transcript
Jun 05, 2023
Akero Therapeutics Inc at JPMorgan Healthcare Conference Transcript
Jan 10, 2023
Akero Therapeutics Inc at H C Wainwright NASH Investor Conference (Virtual) Transcript
Oct 17, 2022
Akero Therapeutics Inc Phase 2B HARMONY Trial Data Presentation Transcript
Sep 13, 2022
Akero Therapeutics Inc Annual Shareholders Meeting Transcript
Jun 02, 2022
Akero Therapeutics Inc at Bank of America Healthcare Conference Transcript
May 11, 2022
Akero Therapeutics Inc at H C Wainwright NASH Investor Conference (Virtual) Transcript
Oct 12, 2021
Akero Therapeutics Inc at Credit Suisse Healthcare Conference (Virtual) Transcript
Nov 09, 2020

Akero Therapeutics Inc at JPMorgan Healthcare Conference Transcript

Jan 08, 2024 / 05:45PM GMT

Release Date Price: €20.8

Transcript

Eric Joseph JPMorgan Chase;Co.;Moderator

&-

All right, so we'll get started here. I'm [Eric Joseph], Senior Biotech Analyst at JPMorgan. Our next presenting company is Akero Therapeutics, and with us to bring us through the story is CEO Andrew Cheng. There is going to be a Q&A session after the presentation. Just raise your hand and we'll bring a mic around. And for folks tuning in via the webcast, feel free to submit questions by clicking the ask-a-question button. With that, Andrew?

Andrew Cheng

Akero Therapeutics Inc - President, Chief Executive Officer, Director

Thank you very much for having us, and we're excited to be back and really to be moving into '24. I think that '23 is an eventful year for us, and it really set us up well for how we're going to be moving forward. So I have to show my Safe Harbor slide to please my legal counsel, but I think that's enough. And so when you think about where we are as a company, we're a clinical-stage Phase 3 company, and that's really exemplified by our press release at the end of last

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.